NASDAQ:ORPN - Bioblast Pharma Stock Price, News, & Analysis

Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN."

Bioblast Pharma's stock reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Bioblast Pharma stock prior to the reverse split would have 13 shares after the split.

Bioblast Pharma is scheduled to release their next quarterly earnings announcement on Monday, April 22nd 2019. View Earnings Estimates for Bioblast Pharma.

News headlines about ORPN stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bioblast Pharma earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the next several days.

Some companies that are related to Bioblast Pharma include Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Auris Medical (EARS), Bohai Pharmaceuticals Group (BOPH), CannTrust (CNTTF), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ) and ERBA Diagnostics (ERBA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), SLS International (SLS), Novavax (NVAX), Sorrento Therapeutics (SRNE), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), CTI BioPharma (CTIC), Portola Pharmaceuticals (PTLA) and Verastem (VSTM).

Shares of ORPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ORPN stock can currently be purchased for approximately $10.78.

Bioblast Pharma has a market capitalization of $4.53 million.

The official website for Bioblast Pharma is http://bioblastpharma.com.

Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The biopharmaceutical company can be reached via phone at 972-3573-6632 or via email at [email protected]